Cargando…
Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going
• Azithromycin (AZM) is a promising drug candidate for the treatment of the COVID-19. • Studies so far on the use of AZM in COVID-19 patients have various methodological limitations. • The evidence on the efficacy of AZM as an adjunct to hydroxychloroquine for COVID-19 is not enough yet. • Combinati...
Autores principales: | Parra-Lara, Luis Gabriel, Martínez-Arboleda, Juan José, Rosso, Fernando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328586/ https://www.ncbi.nlm.nih.gov/pubmed/32622008 http://dx.doi.org/10.1016/j.jgar.2020.06.016 |
Ejemplares similares
-
What prompts clinicians to start antibiotic treatment in COVID-19 patients? An Italian web survey helps us to understand where the doubts lie
por: Colaneri, Marta, et al.
Publicado: (2021) -
Effect of farnesyltransferase inhibitors on SARS-CoV-2
por: Weber, Lea, et al.
Publicado: (2023) -
SARS-CoV-2 positivity in rectal swabs: implication for possible transmission
por: Novazzi, Federica, et al.
Publicado: (2020) -
In vitro evaluation of the virucidal activity of disodium citrate perhydrate (2SCP) disinfectant against SARS-CoV-2
por: Dessilly, Géraldine, et al.
Publicado: (2022) -
Thrombose und COVID-19
por: Tzaneva, Stanislava
Publicado: (2021)